CIPLA Fact Sheet, CIPLA Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA Fact Sheet   (CIPL)


Update: Richa is Very Bullish on this Little-known Smallcap Stock


Here is the latest financial fact sheet of CIPLA. For more details, see the CIPLA quarterly results and CIPLA share price and chart. For a sector overview, read our pharmaceuticals sector report.

CIPLA Price History

Price Rs 944.7
Mkt Cap Rs m 762,285
Vol '000 13.2
P/E X 29.8
P/CF X 22.0
EPS (TTM) Rs 31.7
1 Day % 1.3
No. of shares m 806.91
1 Week % 2.0
1 Month % -2.2
1 Year % -1.9
52 week H/L Rs 1,083.2/850.0
As on Jun 28, 2022 (Close)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

CIPLA Financials

No. of Mths
Year Ending
12
Mar-17
*
12
Mar-18
*
12
Mar-19
*
12
Mar-20
*
12
Mar-21
*
5-Yr Chart
Click to enlarge
CIPLA EQUITY SHARE DATA
High Rs622663678586879 
Low Rs458479484357411 
Sales per share (Unadj.) Rs176.0187.5203.1212.5237.6 
Earnings per share (Unadj.) Rs13.017.618.719.229.8 
Diluted earnings per shareRs12.917.618.719.229.8 
Cash flow per share (Unadj.) Rs29.434.135.233.843.0 
Dividends per share (Unadj.) Rs2.003.003.004.005.00 
Adj. dividends per shareRs1.992.993.004.005.00 
Avg Dividend yield %0.40.50.50.80.8 
Book value per share (Unadj.) Rs155.1175.9185.6194.9226.7 
Adj. book value per shareRs154.7175.5185.3194.7226.6 
Shares outstanding (eoy) m804.51805.12805.70806.24806.46 
Bonus / Rights / Conversions  00000 
Price / Sales ratio x3.13.02.92.22.7 
Avg P/E ratio x41.732.431.024.621.6 
P/CF ratio (eoy) x18.416.816.514.015.0 
Price / Book Value ratio x3.53.23.12.42.8 
Dividend payout %15.417.016.020.816.8 
Avg Mkt Cap Rs m434,516459,723468,032379,858519,826 
No. of employees `000NANANANANA 
Total wages/salary Rs m26,33826,90128,56530,27032,518 
Avg. sales/employee Rs Th00000 
Avg. wages/employee Rs Th00000 
Avg. net profit/employee Rs Th00000 
CIPLA INCOME DATA
Net Sales Rs m141,583150,922163,624171,320191,596 
Other income Rs m2,2873,5774,7663,6942,698 
Total revenues Rs m143,870154,498168,390175,014194,294 
Gross profit Rs m24,75827,48930,97331,80842,487 
Depreciation Rs m13,22913,22813,26311,74710,677 
Interest Rs m1,5941,1421,6841,9741,607 
Profit before tax Rs m12,22216,69520,79121,78232,901 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m1,7982,5015,6956,3128,888 
Profit after tax Rs m10,42414,19415,09615,47024,013 
Gross profit margin %17.518.218.918.622.2 
Effective tax rate %14.715.027.429.027.0 
Net profit margin %7.49.49.29.012.5 
CIPLA BALANCE SHEET DATA
Current assets Rs m88,036108,141124,266117,062132,095 
Current liabilities Rs m33,88938,32237,71543,93145,916 
Net working cap to sales %38.246.352.942.745.0 
Current ratio x2.62.83.32.72.9 
Inventory Days Days4549725068 
Debtors Days Days78987 
Net fixed assets Rs m120,822118,588113,353117,166116,277 
Share capital Rs m1,6091,6101,6111,6131,613 
"Free" reserves Rs m123,207140,019147,941155,487181,232 
Net worth Rs m124,816141,629149,552157,100182,844 
Long term debt Rs m36,45436,62138,30123,69312,028 
Total assets Rs m208,858226,729237,619234,228248,372 
Interest coverage x8.715.613.312.021.5 
Debt to equity ratio x0.30.30.30.20.1 
Sales to assets ratio x0.70.70.70.70.8 
Return on assets %5.86.87.17.410.3 
Return on equity %8.410.010.19.813.1 
Return on capital %8.610.012.013.117.7 
Exports to sales %35.333.133.932.231.3 
Imports to sales %6.813.911.63.410.9 
Exports (fob) Rs m50,05049,88355,41955,17559,951 
Imports (cif) Rs m9,61621,03319,0415,90320,911 
Fx inflow Rs m51,06651,69157,41056,03668,051 
Fx outflow Rs m17,67821,03319,0415,90320,911 
Net fx Rs m33,38830,65838,36850,13347,140 
CIPLA CASH FLOW
From Operations Rs m 23,818 14,628 16,911 30,685 37,552 
From Investments Rs m -13,102 -8,540 -16,687 1,040 -23,872 
From Financial Activity Rs m -13,257 -3,855 -3,487 -29,488 -13,299 
Net Cashflow Rs m -2,478 2,431 -3,451 2,340 509 
* Results Consolidated
Source: Accord Fintech, Equitymaster

Share Holding

Promoters 33.6%
Institution 48.6%
Non-Institution 17.7%
Total 100.0%
Free Float 66.4%
Pledged promoter holdings 0.0%
Shareholding as on Mar 2022
 

Company Information

Regd Off Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg Lower Parel, Mumbai - 400013
E-mail cosecretary@cipla.com Web www.cipla.com
Tel 022-24826000 Fax 022-224826120
Sector PHARMACEUTICALS Group CIPLA Group
Tr Agent K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.), Karvy Selenium Tower B Plot 31-32, Gachibowli Financial District, Nanakramguda
Auditor V. Sankar Aiyar & Co.
CHM: Y K Hamied COMP SEC: Rajendra Chopra YEAR OF INC: 1935 BSE CODE: 500087 FV (Rs): 2 DIV YIELD (%): 0.5

Read: CIPLA 2020-21 Annual Report Analysis

More Pharmaceuticals Company Fact Sheets:   SUN PHARMA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    LUPIN    AUROBINDO PHARMA    

Compare CIPLA With:   SUN PHARMA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    LUPIN    AUROBINDO PHARMA    


Yellow Ad

Advertisement

How to Find One Stock with Crorepati Potential?

There are three critical characteristics that differentiate a common stock from a potential 'crorepati' stock.

And we are going to reveal them during our 'One Stock Crorepati' MEGA summit on 30th June.

If you are interested in finding a potential 'crorepati' stock, don't miss this.

At this MEGA Summit we will reveal details of what we call a 'crorepati' stock...

You just cannot afford to miss this summit for anything.

Learn more



Today's Market

SGX Nifty Down 158 Points, Tata Motors' Price Hike, Ruchi Soya Becomes Patanjali Foods, and Top Buzzing Stocks Today(Pre-Open)

On Tuesday, Indian share markets witnessed a volatile trading session as crude oil prices rebounded following last week's rout.

Views on news

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks (Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Best Monopoly Stocks to Own in 2022 Views On News (Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

Is it Time to Start Buying Stocks Selectively? (Profit Hunter)

Jun 16, 2022

Some sectors have corrected by 50%. Do they merit a look?

The One Smallcap Stock I'll Recommend Now (Profit Hunter)

Jun 21, 2022

This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.

When Will the Stock Market Recover? (Views On News)

Jun 15, 2022

This is how you can tell the market is going to recover.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK CIPLA

MORE ON CIPLA

COMPARE CIPLA WITH

MARKET STATS